Skip to main content
SpringerLink
Log in

Systemic Treatment of Cervical Cancer

  • Chapter
  • First Online:
Book cover Cervical Cancer

  • 2624 Accesses

Abstract

In this section, we review the systemic management of patients with cervical cancer (CC) at different stages of disease: locally advanced, metastatic, or recurrent. The roles of chemoradiotherapy, neoadjuvant chemotherapy, and palliative chemotherapy, as well as of biological therapy, in this pathology are also discussed.

Since the end of the 1990s, different meta-analyses have supported the use of combination chemoradiotherapy based on evidence of an increase in overall survival.

Certain studies have reported that neoadjuvant chemotherapy offers a benefit similar to that obtained with chemoradiotherapy in patients with advanced tumors (larger than 4 cm) or complications such as hydronephrosis but with fewer side effects; however, these inferiority data do not support a change in the standard treatment.

Angiogenesis inhibitors are an efficacious, promising therapy in CC. Recent clinical studies in metastatic and/or recurrent cancer suggest that new signaling pathways in CC can be explored to identify novel molecular targeted therapies in order to obtain better outcomes for patients with this disease.

Some of the therapies for infrequent histologic types are also briefly reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Abbe R. The use of radium in malignant disease. Lancet. 1913;2:524.

    Article  Google Scholar 

  2. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340(15):1154–61.

    Article  CAS  PubMed  Google Scholar 

  3. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340:1137–43.

    Article  CAS  PubMed  Google Scholar 

  4. Peters WA, Liu PY, Barrett RGW. Cisplatin, 5-Fluorouracil plus radiation therapy are superior to radiation therapy as adjunctive therapy in high risk, early stage carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: report of a Phase III inter group study. Presented at Society of Gynecologic Oncologists 30th annual meeting; San Francisco; 5–9 Feb 1999.

    Google Scholar 

  5. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144–53.

    Article  CAS  PubMed  Google Scholar 

  6. Whitney CW, Sause W, Bundy BN, et al. Randomised comparison of fluorouracil plus cisplatin versus hydroxyurea in stage IIB/IVA in carcinoma of the cervix. J Clin Oncol. 1999;17:1339–48.

    Article  CAS  PubMed  Google Scholar 

  7. Tzioras S, Pavlidis N, Paraskevaidis E, et al. Effects of different chemotherapy regimens on survival for advanced cervical cancer: systematic review and meta-analysis. Cancer Treat Rev. 2007;33:24–38.

    Article  CAS  PubMed  Google Scholar 

  8. Claire Vale, Meta-Analysis Group. Collaborators 27. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008;26:5802–12.

    Article  Google Scholar 

  9. DeVita Jr VT, Lawrence TS, Rosenberg SA. Cancer of the cervix, vagina and vulva. In: Cancer principles and practice of oncology. 9th ed. Philadelphia: Lippincott Williams and Wilkins, a Wolters Kluwer Business; 2011.

    Google Scholar 

  10. Dueñas-González A, Cetina-Perez L, Lopez-Graniel C, et al. Pathologic response and toxicity assessment of chemoradiotherapy with cisplatin versus cisplatin plus gemcitabine in cervical cancer: a randomized Phase II study. Int J Radiat Oncol Biol Phys. 2005;61(3):817–23.

    Article  PubMed  Google Scholar 

  11. Cetina L, González-Enciso A, Cantú D, et al. Brachytherapy versus radical hysterectomy after external beam chemoradiation with gemcitabine plus cisplatin: a randomized, phase III study in IB2-IIB cervical cancer patients. Ann Oncol. 2013;24(8):2043–7.

    Article  CAS  PubMed  Google Scholar 

  12. De Azevedo CR, Thuler LC, de Mello MJ, Ferreira CG. Neoadjuvant chemotherapy followed by chemoradiation in cervical carcinoma: a review. Int J Gynecol Cancer. 2016;26:729–36.

    Article  PubMed  Google Scholar 

  13. Tewari KS, Monk BJ. Development of a platform for systemic antiangiogenesis therapy for advanced cervical cancer. Clin Adv Hematol Oncol. 2014;12:737–48.

    PubMed  Google Scholar 

  14. Choi JL, Kim SH. Recurrent uterine cervical carcinoma: spectrum of imaging findings. Korean J Radiol. 2000;1:198–207.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Peiriti M, Zapardiel I, Zanagnolo V. Management of recurrent cervical cancer: a review of the literatura. Surg Oncol. 2012;21:e59–66.

    Article  Google Scholar 

  16. Sardain H, Lavoue V, Redpath M, et al. Curative pelvic exenteration for recurrent cervical carcinoma in the era of concurrent chemotherapy and radiation therapy. A systematic review. Eur J Surg Oncol. 2015;41(8):975–85.

    Article  CAS  PubMed  Google Scholar 

  17. López-Graniel C, Dolores R, Cetina L, et al. Pre-exenterative chemotherapy, a novel therapeutic approach for patients with persistent or recurrent cervical cancer. BMC Cancer. 2005;5:118.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Long HJ. Management of metastatic cervical cancer: review of the literatura. J Clin Oncol. 2007;25:2966–74.

    Article  CAS  PubMed  Google Scholar 

  19. Bononi P, Blessing JA, McQuellon. Randomized trial of three of cisplatin dose schedules in squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1985;3:79–85.

    Google Scholar 

  20. Moore DH, Blessing JA, McQuellon RP. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squeamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 2004;22:3113–9.

    Article  CAS  PubMed  Google Scholar 

  21. Long HJ, Bundy BN, Grendys EC. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005;23(21):4626–33.

    Article  CAS  PubMed  Google Scholar 

  22. Monk BJ, Sill MW, McMeekin S, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB recurrent, or persistent cervical carcinoma: a gynecologic Oncology Group Study. J Clin Oncol. 2009;27:4649–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Kitagawa R, Katsumata N, Shibata T. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomize phase III trial: JCOGO 0505. J Clin Oncol. 2015;33:2129–35.

    Article  CAS  PubMed  Google Scholar 

  24. Weinstein IB, Begemann M, Zhou P, et al. Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. Clin Cancer Res. 1997;3:2696–702.

    CAS  PubMed  Google Scholar 

  25. Zagouri F, Sergentains T, Chrysikos D, et al. Molecularly targeted therapies in cervical cáncer. A systematic review. Gynecol Oncol. 2012;126:291–303.

    Article  CAS  PubMed  Google Scholar 

  26. Goncalves A, Fabbro M, Lhomme C, et al. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol. 2008;108:42–6.

    Article  CAS  PubMed  Google Scholar 

  27. Schilder RJ, Sill MW, Lee YC, et al. A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Int J Gynecol Cancer. 2009;19:929–33.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Monk BJ, Mas Lopez L, Zarba JJ, et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol. 2010;28:3562–9.

    Article  CAS  PubMed  Google Scholar 

  29. Cetina L, Crombet T, Jiménez R, et al. A phase II trial to evaluate Nimotuzumab as second- or third-line treatment or more in patients with recurring or persistent locorregionally advanced or metastatic cervical cancer. Cancer Biol Ther. 2015;16(5):684–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Guidi AJ, Abu-Jawdeh G, Berse B, et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst. 1995;87:1237–45.

    Article  CAS  PubMed  Google Scholar 

  31. Wright JD, Viviano D, Powell MA, et al. Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecol Oncol. 2006;103:489–93.

    Article  CAS  PubMed  Google Scholar 

  32. Monk BJ, Sill MW, Burger RA, et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecology Oncology Group study. J Clin Oncol. 2009;27:1069–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Shefter TE, Winter K, Kwon JS, et al. A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417. Int J Radiat Oncol Biol Phys. 2012;83(4):1179–84.

    Article  Google Scholar 

  34. Sonpavde G, Hutson TE. Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep. 2007;9:115–9.

    Article  CAS  PubMed  Google Scholar 

  35. Monk BJ, Pandite LN. Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. J Clin Oncol. 2011;29:4845.

    Article  PubMed  Google Scholar 

  36. Munster P, Marchion D, Bicaku E, et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J Clin Oncol. 2007;25:1979–85.

    Article  CAS  PubMed  Google Scholar 

  37. Coronel J, Cetina L, Pacheco I, et al. A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. Med Oncol. 2011;28(S1):540–6.

    Article  CAS  Google Scholar 

  38. Chen J, Macdonald OK, Gaffner DK. Incidence, mortality, and prognostic factors of small cell carcinoma of the cérvix. Obstet Gynecol. 2008;111:1394–402.

    Article  PubMed  Google Scholar 

  39. McCusker ME, Coté TR, Clegg LX, et al. Endocrine tumors of the uterine cérvix: incidence demographics, and survival with comparison to squeamous cell carcinoma. Gynecol Oncol. 2003;88:333–9.

    Article  PubMed  Google Scholar 

  40. Albores-Saavedra J, Gersell D, Gilks CB, et al. Terminology of endocrine tumors of the uterine cervix. results of a workshop sponsored by the College of American Pathologist and the National Cancer Institute. Arch Pathol Lab Med. 1997;121:34–9.

    CAS  PubMed  Google Scholar 

  41. Sheets EE, Berman ML, Hrountas CK, et al. Surgical treated, early-stage neuroendocrine small-cell cervical carcarcinoma. Obstet Gynecol. 1988;71:10–6.

    CAS  PubMed  Google Scholar 

  42. Viswanathan AN, Deavers MT, Jhingran A, et al. Small cell neuroendocrine carcinoma of the cervix:outcome and patterns of recurrence. Gynecol Oncol. 2004;93:27–33.

    Article  CAS  PubMed  Google Scholar 

  43. Zivanovic O, Leitao Jr MM, Park KJ, et al. Small cell neuroendocrine carcinoma of the cervix: analysis of outcome, recurrencia pattern and the impact of platinum-base combination chemotherapy. Gynecol Oncol. 2009;112:590–3.

    Article  CAS  PubMed  Google Scholar 

  44. Cohen JP, Kapp DS, Shin JY, et al. Small cell carcinoma of the cervix: treatment and survival outcomes of 188 patients. Am J Obstet Gynecol. 2010;203:347.e1–6.

    Article  Google Scholar 

  45. Hoskins PJ, Swwenerton KD, Pike JA, et al. Small cell carcinoma of the cervix: fourteen years of experience at a single institution using a combined-modality régimen of involved-field irradiation and platinum-based combination chemotherapy. J Clin Oncol. 2003;21:3495–501.

    Article  CAS  PubMed  Google Scholar 

  46. Melnick S, Cole P, Anderson D, et al. Rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix. N Engl J Med. 1987;316:514–6.

    Article  CAS  PubMed  Google Scholar 

  47. Nasu K, Takai N, Narahara H. Multimodal treatment for glassy cell carcinoma of the uterine cervix. J Obstet Gynaecol Res. 2009;35(3):584–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Instituto Nacional de Cancerología-México, Av. San Fernando No 22, Col. Toriello Guerra, Tlalpan, Mexico City, Mexico, 14070

    Flavia Morales-Vásquez MD, MSc, Claudia Cano-Blanco MD & Jorge Martínez-Tlahuel MD

  2. Clinical Research Department, Instituto Nacional de Cancerología-México, Mexico City, Mexico

    Jaime Alberto Coronel-Martínez MSc & Lucely Cetina-Pérez MSc

  3. Department of Medical Oncology, Hospital Español de México, Mexico City, Mexico

    Julio César Velasco-Rodríguez MD

  4. Department Surgical Oncology, Instituto Nacional de Cancerología-México, Mexico City, Mexico

    Horacio N. López-Basave MD, MSc

  5. Department of Clinical Investigation, Instituto Nacional de Cancerología-México, Mexico City, Mexico

    Jaime G. de la Garza-Salazar MD

Authors
  1. Flavia Morales-Vásquez MD, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claudia Cano-Blanco MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jaime Alberto Coronel-Martínez MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lucely Cetina-Pérez MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jorge Martínez-Tlahuel MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Julio César Velasco-Rodríguez MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Horacio N. López-Basave MD, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jaime G. de la Garza-Salazar MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Instituto Nacional de Cancerología, Mexico City, Mexico

    Jaime G. de la Garza-Salazar

  2. Instituto Nacional de Cancerología, Mexico City, Mexico

    Flavia Morales-Vásquez

  3. Instituto Nacional de Cancerología, Mexico City, Mexico

    Abelardo Meneses-Garcia

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Morales-Vásquez, F. et al. (2017). Systemic Treatment of Cervical Cancer. In: de la Garza-Salazar, J., Morales-Vásquez, F., Meneses-Garcia, A. (eds) Cervical Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-45231-9_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-45231-9_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-45230-2

  • Online ISBN: 978-3-319-45231-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation